Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.

Jörg, L; Pecaric-Petkovic, T; Reichenbach, S; Coslovsky, M; Stalder, O; Pichler, W; Hausmann, O (2018). Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Clinical and experimental allergy, 48(2), pp. 196-204. Blackwell Scientific Publications 10.1111/cea.13066

[img] Text
Jörg ClinExpAllergy 2017.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (216kB) | Request a copy
[img]
Preview
Text
Jörg ClinExpAllergy 2017_manuscript.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (185kB) | Preview

BACKGROUND Omalizumab has been shown to be effective in treating chronic spontaneous urticaria (CSU). The reduction in FcεRI receptor density on the surface of basophils and mast cells is thought to play a major role in its effectiveness. We conducted a double-blind, randomized, placebo-controlled trial to investigate the mode of action of omalizumab in patients with antihistamine-resistant CSU. METHODS Thirty patients were randomized in a 2:1 ratio to receive either 300 mg omalizumab or placebo. Four monthly applications of omalizumab/placebo were followed up with a visit 2 months after the last injection. The primary endpoint was the FcεRI receptor density change on basophils. RESULTS Omalizumab led to a significant reduction in FcεRI receptor density on basophils as soon as 1 week after the first injection: baseline omalizumab vs placebo group, 80.31 ± 47.18 × 10³ vs 78.29 ± 45.09 × 10³ receptors/basophil ± SD; 1 week, 72.89 ± 47.79 × 10³ vs 27.83 ± 20.87 × 10³, P = .001. This effect continued during the treatment phase and persisted for 2 months after the last injection: 93.81 ± 56.50 × 10³ vs 21.09 ± 15.23 × 10³, P = .002. Values for basophil "releasability" and the basophil activation test (CU-BAT) of patient serum using donor basophils were unchanged despite treatment: CU-BAT, CD63 10.75% (7.35) in the placebo group vs 8.35% (15.20) in the omalizumab group, P = .778. CONCLUSION We demonstrated a rapid reduction of FcεRI receptor density on basophils following treatment with omalizumab. Because CU-BAT using well-characterized, omalizumab-naïve donor basophils did not change during the treatment phase, autoreactive serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab on basophils. To predict the omalizumab response time and to monitor disease, FcεRI density and CU-BAT might be promising cellular-based assays.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Jörg-Walther, Lukas Emanuel; Reichenbach, Stephan; Coslovsky, Michael; Stalder, Odile and Hausmann, Oliver

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0954-7894

Publisher:

Blackwell Scientific Publications

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

14 Dec 2017 09:44

Last Modified:

13 Dec 2018 02:30

Publisher DOI:

10.1111/cea.13066

PubMed ID:

29164723

Uncontrolled Keywords:

FcεRI receptor density basophil activation test chronic idiopathic urticaria chronic spontaneous urticaria omalizumab

BORIS DOI:

10.7892/boris.107982

URI:

https://boris.unibe.ch/id/eprint/107982

Actions (login required)

Edit item Edit item
Provide Feedback